Jane Rady joined Glaukos as SVP Corporate Strategy & Business Development to help lead the strategic vision for this growth company focused on products addressing major unmet medical needs in ophthalmology. Prior to joining Glaukos, Jane spent 16 years at AMO, now Johnson & Johnson Surgical Vision in various leadership capacities including business development, strategic planning, R&D, regulatory affairs, medical marketing, and government affairs.
Jane’s experience spans disciplines outside of ophthalmology. She began her career with Abbott Laboratories in research/quality functions moving into management heading the development and manufacturing of Abbokinase and research in other biologics including TPA, erythropoietin and interferon. She joined Monsanto to head their venture investment efforts in biotechnology as it related to products for agriculture, nutrition and pharmaceuticals. With the acquisition of GD Searle by Monsanto, Jane became a member of the leadership team at Searle heading business development and strategic planning as well as becoming the President and General Manager of Lorex, the joint venture between Searle and Synthelabo that developed and launched Ambien in the US market.
Over the years, Jane has been active in organizations supporting ophthalmology including as a board member of MDMA, board member of OWL, founder and chair of the SoCal chapter of OWL, advisory board of OIS and as a member of UCI’s biomedical advisory board.
Jane holds a BS and MS from the University of Illinois and an MBA from Northwestern University Kellogg Graduate School of Management. She and her husband live in Irvine, California and their son in Chicago, Illinois.